At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 32 enrolled
Drug / intervention
acyclovir +1 moredrug
Likely dose
acyclovir 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
In Brief
A Phase 4 clinical trial evaluating acyclovir and valacyclovir for HSV Infection and HIV Infection. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether treating HSV-2 with either valacyclovir or acyclovir is more effective in suppressing HIV-1 virus levels in people co-infected with HIV-1 and HSV-2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHSV Infection, HIV Infection
CountriesKenya
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartFeb 2010
Primary CompletionNov 2010
Study CompletionDec 2010
TodayJul 2026
First PostedDec 4, 2009
Enrollment StartFeb 1, 2010
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.6 years ago
Interventions
acyclovirdrug
acyclovir 400 mg orally, twice daily for 12 weeks
valacyclovirdrug
valacyclovir 1.5 g orally, twice daily, for 12 weeks